May. 5 at 11:54 PM
$ALGS story obviously hinges on clinical success and in biotech that’s always binary. There’s a reason 90% of bios fail. Larry has burned through a lot of cash (heard something like
$600M+ since inception), which at that rate brings real / further dilution risk if timelines slip. Valuation already assumes success, so any setback or delay could hit hard. Tough watching it sit in the portfolio, but still hoping for that 1,000% move (up…ha) one day.
